These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 7199538)

  • 21. The fibrinolytic system in man.
    Collen D; Lijnen HR
    Crit Rev Oncol Hematol; 1986; 4(3):249-301. PubMed ID: 2420482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progressive cross-linking of fibrin gamma chains increases resistance to fibrinolysis.
    Siebenlist KR; Mosesson MW
    J Biol Chem; 1994 Nov; 269(45):28414-9. PubMed ID: 7961782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
    Nielsen VG
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Fibrinolysis by Coagulation Factor XIII.
    Rijken DC; Uitte de Willige S
    Biomed Res Int; 2017; 2017():1209676. PubMed ID: 28761875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism.
    Reed GL; Houng AK
    Circulation; 1999 Jan; 99(2):299-304. PubMed ID: 9892598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
    Collen D
    J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin.
    Reed GL; Matsueda GR; Haber E
    Thromb Haemost; 1992 Sep; 68(3):315-20. PubMed ID: 1279832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of phenylglyoxal-modified alpha2-antiplasmin on urokinase-induced fibrinolysis.
    Lee KN; Lee SC; Jackson KW; Tae WC; Schwartzott DG; McKee PA
    Thromb Haemost; 1998 Oct; 80(4):637-44. PubMed ID: 9798984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The myeloperoxidase product, hypochlorous acid, reduces thrombus formation under flow and attenuates clot retraction and fibrinolysis in human blood.
    Misztal T; Golaszewska A; Tomasiak-Lozowska MM; Iwanicka M; Marcinczyk N; Leszczynska A; Chabielska E; Rusak T
    Free Radic Biol Med; 2019 Sep; 141():426-437. PubMed ID: 31279970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasminogen, plasminogen activator, and platelets in the regulation of clot lysis. Reconstitution and patient studies.
    Carroll RC; Radcliffe RD; Taylor FB; Gerrard JM
    J Lab Clin Med; 1982 Dec; 100(6):986-96. PubMed ID: 6890569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physiological role of alpha 2-plasmin inhibitor in rats.
    Kumada T; Abiko Y
    Thromb Res; 1984 Oct; 36(2):153-63. PubMed ID: 6506034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic fibrinolysis: combined effects of plasminogen activators and an antibody that inhibits alpha 2-antiplasmin.
    Reed GL; Matsueda GR; Haber E
    Proc Natl Acad Sci U S A; 1990 Feb; 87(3):1114-8. PubMed ID: 1689060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents.
    Farrehi PM; Zhu Y; Fay WP
    J Thromb Thrombolysis; 2001 Dec; 12(3):273-81. PubMed ID: 11981110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of activated coagulation factor XII in overall clot stability and fibrinolysis.
    Konings J; Hoving LR; Ariëns RS; Hethershaw EL; Ninivaggi M; Hardy LJ; de Laat B; Ten Cate H; Philippou H; Govers-Riemslag JW
    Thromb Res; 2015 Aug; 136(2):474-80. PubMed ID: 26153047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis.
    Lee KN; Jackson KW; McKee PA
    Thromb Res; 2002 Feb; 105(3):263-70. PubMed ID: 11927133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.
    Kluft C; Nieuwenhuis HK; Rijken DC; Groeneveld E; Wijngaards G; van Berkel W; Dooijewaard G; Sixma JJ
    J Clin Invest; 1987 Nov; 80(5):1391-400. PubMed ID: 2445779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation by alpha 2-antiplasmin and fibrin of the activation of plasminogen with recombinant staphylokinase in plasma.
    Silence K; Collen D; Lijnen HR
    Blood; 1993 Aug; 82(4):1175-83. PubMed ID: 7688990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis.
    Gould TJ; Vu TT; Stafford AR; Dwivedi DJ; Kim PY; Fox-Robichaud AE; Weitz JI; Liaw PC
    Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2544-53. PubMed ID: 26494232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
    Hare TR; Gardell SJ
    Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R; Black J; Gurewich V
    J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.